Latest Certolizumab pegol Stories
LONDON and BRUSSELS, May 27, 2011 /PRNewswire/ -- UCB today announced data which showed that the addition of CimziaÂ® (certolizumab pegol) to current therapy was associated with a rapid and consistent clinical response in a diverse group of rheumatoid arthritis (RA) patients.
BRUSSELS, May 16, 2011 /PRNewswire/ -- The ACR hybrid score, a new measure of response to RA treatment recently developed by the American College of Rheumatology, demonstrated improved sensitivity compared to traditional ACR responses, according to recently published results in Arthritis Care & Research.
BRUSSELS, May 10, 2011 /PRNewswire/ -- UCB announced results from a post hoc analysis of the RAPID 2 study, published in the Annals of Rheumatic Diseases, which showed CimziaÂ®, the only approved PEGylated anti-TNF, plus methotrexate (MTX) provided rapid relief from a broad range of symptoms associated with the burden of moderate to severe active rheumatoid arthritis (RA).
BRUSSELS, May 10, 2011 /PRNewswire/ -- UCB announced today results from a post hoc analysis of the RAPID 1 study published in the Journal of Rheumatology.
Some biologic drugs may be safer than others according to a new systematic review by Cochrane researchers.
BRUSSELS and INCLINE VILLAGE, Nev., Feb. 8, 2011 /PRNewswire/ -- UCB SA (Euronext Brussels: UCB), on behalf of its affiliate UCB Pharma S.A. (UCB), and PDL BioPharma, Inc.
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.